gsk201204206k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 
 
  
 
 




 

 
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of an increase in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1467.31 pence per Share on 19 April 2012, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 12 April 2012.
 
 
 
 
Ordinary Shares
 
Dr M M Slaoui
 
342.385
Mr S M Bicknell
 
0.151
Mr M Dunoyer
 
149.508
Mr E J Gray
 
526.549
Mr S A Hussain
 
331.646
Mr D S Redfern
 
237.738
Ms C Thomas
 
179.719
Mr P C Thomson
 
139.895
Dr P J T Vallance
 
151.316
 
Mr C Weber
328.306
 
Mrs V A Whyte
14.709
 
 
 
The Company was advised of this information on 20 April 2012.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
V A Whyte
Company Secretary
 
20 April 2012
 


 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 20, 2012 
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc